Nestle Health Science

Amazentis SA is a life science company based in Lausanne, Switzerland, founded in 2007. The company specializes in the research and development of bioactive ingredients aimed at advanced therapeutic nutrition, particularly for the aging population. Amazentis focuses on creating products that enhance mitochondrial health, addressing age-related muscle decline by improving mitochondrial activity. Utilizing proprietary technology, the company mimics the effects of certain foods, like pomegranates, to repair damage in mitochondria and promote an active lifestyle. Through its innovative approach, Amazentis aims to meet specific health needs, particularly in hospital settings, by optimizing muscle function and overall well-being.

Ruipeng Pet Hospital is a Shenzhen-based pet medical and beauty care hospital operator, which covers pet healthcare, foster care, bathing, SPA, beauty, food, entertainment and leisure services.

Puravida is a manufacturer and supplier of nutrient-dense, clean-label products aimed at promoting an organic lifestyle. The company offers a diverse range of items, including vitamins, nutrients, proteins, functional plant-based foods, and body care products. Their product lineup features chestnut cream, spices, healthy snacks, natural beauty items, oral care products, and various supplements. By focusing on these offerings, Puravida contributes to the shift towards healthier diets while addressing issues of sustainability and global food security.

Orgain, Inc. is a producer of nutritional and organic food and supplements, established in 2008 and headquartered in Irvine, California. The company specializes in a range of products designed to promote health and wellness, including protein powders (such as vegan and grass-fed whey), nutritional powders, and various protein shakes for both adults and children. Additionally, Orgain offers protein bars, nutritional bars, and meal replacements tailored for weight management and daily nutrition needs. Committed to using high-quality ingredients, Orgain emphasizes clean nutrition without artificial additives or preservatives. Its products are available through both retail and online channels, catering to a diverse customer base seeking convenient and nutritious options.

NBTY, Inc., is an American manufacturer of vitamins and nutritional supplements which are distributed under many third party brands in the United States and internationally.

ProciseDx specializes in point-of-care testing solutions that provide accurate and high-quality diagnostic results. By offering a range of diagnostic instruments, the company enables physicians to deliver real-time, lab-quality results directly in their offices, retail clinics, and urgent care settings. This approach allows both physicians and patients to make more informed decisions, as patients can leave appointments with definitive answers rather than the need for follow-up visits. Through its innovative diagnostic tests, ProciseDx aims to improve the healthcare experience by facilitating immediate access to vital information.

Aimmune Therapeutics is a biopharmaceutical company that focuses on developing and commercializing treatments for peanut and other food allergies. The company's primary product, PALFORZIA, is designed to desensitize patients to peanut allergens through a method known as Characterized Oral Desensitization Immunotherapy (CODIT). In addition to PALFORZIA, Aimmune is conducting research and development on other CODIT candidates, including AR201, which is in Phase II clinical trials for treating egg allergies in pediatric and young adult patients, as well as potential treatments for cow’s milk allergy. Aimmune has established strategic collaborations with Nestlé Health Science to advance food allergy therapies and has clinical partnerships with Regeneron and Sanofi to explore the use of PALFORZIA alongside additional treatments. Founded in 2011 and headquartered in Brisbane, California, Aimmune Therapeutics aims to provide innovative solutions for managing life-threatening food allergies.

IM HealthScience develops healthcare products aimed at enhancing overall health and wellness, particularly for conditions with significant unmet medical needs. The company is known for its innovative products such as IBgard® and FDgard®, which are designed for the dietary management of Irritable Bowel Syndrome (IBS) and Functional Dyspepsia (FD), respectively. In 2017, IM HealthScience expanded its offerings by acquiring Fiber Choice®, a line of prebiotic fibers. Additionally, the company's subsidiary, Physician’s Seal®, markets REMfresh®, a continuous release and absorption melatonin supplement that supports sleep. IM HealthScience sells its products through online platforms and retail channels, focusing on various gastrointestinal conditions including diverticulosis, ulcerative colitis, and Crohn's disease.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Vital Proteins, LLC is a manufacturer and seller of whole food-based nutrition products, primarily focusing on collagen. The company's offerings include collagen supplements, collagen creamers, beauty waters, bone broths, and various greens and veggies products, all aimed at promoting health, fitness, and natural beauty. Vital Proteins emphasizes the use of sustainably-sourced ingredients, with its collagen derived from pasture-raised Brazilian bovine hides. The company operates out of Elk Grove Village, Illinois, and provides its products through online sales channels. As of July 2020, it functions as a subsidiary of Nestlé Health Science S.A., further expanding its reach in the health supplement market.

Aimmune Therapeutics is a biopharmaceutical company that focuses on developing and commercializing treatments for peanut and other food allergies. The company's primary product, PALFORZIA, is designed to desensitize patients to peanut allergens through a method known as Characterized Oral Desensitization Immunotherapy (CODIT). In addition to PALFORZIA, Aimmune is conducting research and development on other CODIT candidates, including AR201, which is in Phase II clinical trials for treating egg allergies in pediatric and young adult patients, as well as potential treatments for cow’s milk allergy. Aimmune has established strategic collaborations with Nestlé Health Science to advance food allergy therapies and has clinical partnerships with Regeneron and Sanofi to explore the use of PALFORZIA alongside additional treatments. Founded in 2011 and headquartered in Brisbane, California, Aimmune Therapeutics aims to provide innovative solutions for managing life-threatening food allergies.

Persona (formerly Vitamin Packs), the next generation personalized nutrition program, helps consumers take the guesswork out of the dietary supplement aisle by using researched science to deliver personalized nutrition safely and conveniently. Persona uses thousands of personalized inputs to recommend supplements that meet individual needs and lifestyle habits. As a proud supporter of Vitamin Angels®, every Persona order provides two children who are malnourished a full year of vitamins. To learn more about Persona, please visit www.personanutrition.com.

Amazentis SA is a life science company based in Lausanne, Switzerland, founded in 2007. The company specializes in the research and development of bioactive ingredients aimed at advanced therapeutic nutrition, particularly for the aging population. Amazentis focuses on creating products that enhance mitochondrial health, addressing age-related muscle decline by improving mitochondrial activity. Utilizing proprietary technology, the company mimics the effects of certain foods, like pomegranates, to repair damage in mitochondria and promote an active lifestyle. Through its innovative approach, Amazentis aims to meet specific health needs, particularly in hospital settings, by optimizing muscle function and overall well-being.

Aimmune Therapeutics is a biopharmaceutical company that focuses on developing and commercializing treatments for peanut and other food allergies. The company's primary product, PALFORZIA, is designed to desensitize patients to peanut allergens through a method known as Characterized Oral Desensitization Immunotherapy (CODIT). In addition to PALFORZIA, Aimmune is conducting research and development on other CODIT candidates, including AR201, which is in Phase II clinical trials for treating egg allergies in pediatric and young adult patients, as well as potential treatments for cow’s milk allergy. Aimmune has established strategic collaborations with Nestlé Health Science to advance food allergy therapies and has clinical partnerships with Regeneron and Sanofi to explore the use of PALFORZIA alongside additional treatments. Founded in 2011 and headquartered in Brisbane, California, Aimmune Therapeutics aims to provide innovative solutions for managing life-threatening food allergies.

Axcella is a clinical-stage biotechnology company dedicated to addressing complex diseases through the use of endogenous metabolic modulator (EMM) compositions. By integrating biological pathways with advancements in systems biology and machine learning, Axcella aims to identify protein nutrients in the human diet that possess significant pharmacological effects. The company has developed a proprietary platform that has been clinically validated across various indication areas, including muscle, neurodegenerative, and liver conditions. Axcella's innovative approach seeks to enhance health outcomes by leveraging the therapeutic potential of EMMs.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Aimmune Therapeutics is a biopharmaceutical company that focuses on developing and commercializing treatments for peanut and other food allergies. The company's primary product, PALFORZIA, is designed to desensitize patients to peanut allergens through a method known as Characterized Oral Desensitization Immunotherapy (CODIT). In addition to PALFORZIA, Aimmune is conducting research and development on other CODIT candidates, including AR201, which is in Phase II clinical trials for treating egg allergies in pediatric and young adult patients, as well as potential treatments for cow’s milk allergy. Aimmune has established strategic collaborations with Nestlé Health Science to advance food allergy therapies and has clinical partnerships with Regeneron and Sanofi to explore the use of PALFORZIA alongside additional treatments. Founded in 2011 and headquartered in Brisbane, California, Aimmune Therapeutics aims to provide innovative solutions for managing life-threatening food allergies.

Phagenesis Limited is focused on developing medical device technology aimed at treating dysphagia, a condition that impairs swallowing, often resulting from strokes or brain injuries. The company's primary product, Phagenyx, consists of a base station that delivers electrical stimulations to the patient and records pertinent information, along with a catheter that is introduced through the nose to stimulate the pharynx. This innovative approach leverages the brain's ability to relearn lost functions through neuroplasticity, effectively aiding patients in regaining control over their swallowing mechanisms. Founded in 2007 and based in Manchester, United Kingdom, Phagenesis emphasizes research and evidence-based solutions, with foundational work led by Professor Shaheen Hamdy of the University of Manchester, whose findings have been published in prestigious medical journals.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Axcella is a clinical-stage biotechnology company dedicated to addressing complex diseases through the use of endogenous metabolic modulator (EMM) compositions. By integrating biological pathways with advancements in systems biology and machine learning, Axcella aims to identify protein nutrients in the human diet that possess significant pharmacological effects. The company has developed a proprietary platform that has been clinically validated across various indication areas, including muscle, neurodegenerative, and liver conditions. Axcella's innovative approach seeks to enhance health outcomes by leveraging the therapeutic potential of EMMs.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, that specializes in developing ecobiotic microbiome therapeutics aimed at restoring health by correcting dysbiosis in the microbiome. The company is advancing several product candidates, with its lead therapy, SER-109, currently in Phase III clinical trials to prevent recurrence of Clostridium difficile infection (CDI). Additional candidates in development include SER-287 for ulcerative colitis, SER-401 for use with checkpoint inhibitors in metastatic melanoma, and SER-301 for inflammatory bowel disease. The company is also working on SER-262 to address initial CDI recurrences and SER-155 to support patients after allogeneic hematopoietic stem cell transplants. Seres Therapeutics has established collaboration agreements with organizations such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as partnerships with AstraZeneca. Founded in 2010, the company has evolved from its original name, Seres Health, Inc., reflecting its focus on microbiome-based therapeutic solutions.

Vital Foods specializes in the development, production, and sale of kiwifruit-based food products aimed at promoting long-term intestinal health. The company offers a range of items, including Kiwi Crush, a nutritious kiwifruit drink enriched with essential vitamins, antioxidants, and minerals. Additionally, it provides Phloe Bowel Health, which features a kiwifruit extract available in both capsules and chewable tablets, utilizing prebiotics, enzymes, and fiber derived from fresh kiwifruit. Vital Foods focuses on delivering natural digestive aids to customers at accessible prices, supporting their overall well-being.

Prometheus Biosciences, established in 1995 and headquartered in San Diego, California, specializes in developing and commercializing innovative pharmaceutical and diagnostic products. The company's portfolio includes tests that enable physicians to provide personalized patient care, such as monitoring drug and anti-drug antibody levels, diagnosing and prognosticating inflammatory bowel disease (IBD), and detecting celiac disease and lactose intolerance. Prometheus also offers therapeutic products like Entocort EC for treating Crohn's disease and has agreements to develop and market other drugs. The company's commitment to innovation positions it as a leader in precision healthcare, particularly in gastroenterology.

Prometheus Biosciences, established in 1995 and headquartered in San Diego, California, specializes in developing and commercializing innovative pharmaceutical and diagnostic products. The company's portfolio includes tests that enable physicians to provide personalized patient care, such as monitoring drug and anti-drug antibody levels, diagnosing and prognosticating inflammatory bowel disease (IBD), and detecting celiac disease and lactose intolerance. Prometheus also offers therapeutic products like Entocort EC for treating Crohn's disease and has agreements to develop and market other drugs. The company's commitment to innovation positions it as a leader in precision healthcare, particularly in gastroenterology.